LP
BCYC

LMR Partners’s Bicycle Therapeutics BCYC Stock Holding History

LMR Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40,283
Closed -$1.77M – 1294
2022
Q1 		$1.77M Buy
40,283
+283
+0.7% +$13.2K 0.02% 613
2021
Q4 		$2.44M Buy
+40,000
New +$2.21M 0.02% 425

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

LMR Partners's BCYC Position: Q2 2022 in Review

LMR Partners sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 40,283 shares — an estimated $1.77M sold.

LMR Partners first reported a position in BCYC in Q4 2021 and held it in 2 quarters. The position peaked at $2.44M in Q4 2021. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

  • LMR Partners reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
  • LMR Partners sold 40,283 Bicycle Therapeutics shares in Q2 2022, an estimated $1.77M.
  • LMR Partners first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 2 quarters.
  • LMR Partners's Bicycle Therapeutics position peaked at $2.44M in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.